Goldman Sachs Group Inc Amryt Pharma PLC Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 14, 2024	BUY	$7.0 - $14.77 $1.07 Million - $2.27 Million	153,359 Added 1445.56%	163,968 $2.39 Million
Q1 2023 May 11, 2023	BUY	$7.0 - $14.77 $1.15 Million - $2.42 Million	163,968 New	163,968 $2.39 Million
Q3 2022 May 14, 2024	SELL	$6.8 - $8.01 $4,651 - $5,478	-684 Reduced 6.06%	10,609 $73,000
Q3 2022 Nov 10, 2022	SELL	$6.8 - $8.01 $4,651 - $5,478	-684 Reduced 6.06%	10,609 $73,000
Q2 2022 May 14, 2024	BUY	$6.85 - $8.87 $77,357 - $100,168	11,293 New	11,293 $79,000
Q2 2022 Aug 15, 2022	SELL	$6.85 - $8.87 $3,651 - $4,727	-533 Reduced 4.51%	11,293 $79,000
Q1 2022 May 16, 2022	SELL	$6.3 - $10.86 $20,689 - $35,664	-3,284 Reduced 21.73%	11,826 $98,000
Q4 2021 Feb 14, 2022	SELL	$9.44 - $12.24 $112,439 - $145,790	-11,911 Reduced 44.08%	15,110 $163,000
Q3 2021 Nov 10, 2021	BUY	$9.63 - $12.47 $260,212 - $336,951	27,021 New	27,021 $326,000

142K

Ticker AMYT
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 64,177,000
Description
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with ...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.